AI Insight
Retinoblastoma is the most common primary eye cancer in children, arising from cone photoreceptor precursor cells in the developing retina. The cancer is primarily caused by biallelic inactivation of the RB1 tumor suppressor gene, while fewer than 2% of cases show MYCN oncogene amplification instead. Despite being largely curable, the disease demonstrates significant global health disparities in outcomes.
Why it matters
Understanding the genetic mechanisms driving retinoblastoma enables targeted treatment approaches and genetic counseling for affected families. The stark disparities in survival rates between different regions highlight critical gaps in access to diagnosis and treatment that need to be addressed to ensure equitable outcomes for all children with this curable cancer.
Understand the Science
Retinoblastoma, the most common primary intraocular malignancy of childhood, represents a substantial global health equity concern, exemplifying profound disparities in global burden and outcome despite being a largely curable cancer. Retinoblastoma is thought to arise from cone photoreceptor precursor cells of the developing retina, mainly driven by biallelic inactivation of the RB1 tumour suppressor gene. Fewer than 2% of cases have no detectable RB1 pathogenic variant; approximately half of these cases instead show high-level amplification of the MYCN oncogene.
Source: [Seminar] Retinoblastoma